{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:30:59Z","timestamp":1789871459264,"version":"4.0.1"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1097\/md.0000000000000609","type":"journal-article","created":{"date-parts":[[2015,3,18]],"date-time":"2015-03-18T20:18:48Z","timestamp":1426709928000},"page":"e609","source":"Crossref","is-referenced-by-count":22,"title":["Network Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1097","volume":"94","author":[{"given":"Gui-Qi","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Qing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Qian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Qian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Rui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Braddock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210226","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(03)13808-1","article-title":"Primary biliary cirrhosis.","volume":"362","author":"Talwalkar","year":"2003","journal-title":"Lancet"},{"key":"R2-10-20210226","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/hep.20103","article-title":"A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results.","volume":"39","author":"Kaplan","year":"2004","journal-title":"Hepatology (Baltimore, MD)"},{"key":"R3-10-20210226","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology (Baltimore, MD)"},{"key":"R4-10-20210226","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.","volume":"19","author":"Heathcote","year":"1994","journal-title":"Hepatology (Baltimore, MD)"},{"key":"R5-10-20210226","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis.","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"key":"R6-10-20210226","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1053\/gast.1996.v110.pm8613058","article-title":"Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis.","volume":"110","author":"Lindor","year":"1996","journal-title":"Gastroenterology"},{"issue":"3","key":"R7-10-20210226","first-page":"CD000551","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis.","author":"Gong","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"R8-10-20210226","first-page":"CD000551","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis.","volume":"12","author":"Rudic","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R9-10-20210226","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0168-8278(96)80191-7","article-title":"Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: a prospective randomized study.","volume":"24","author":"Ikeda","year":"1996","journal-title":"J Hepatol"},{"key":"R10-10-20210226","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/hep.510240520","article-title":"A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis.","volume":"24","author":"Poupon","year":"1996","journal-title":"UDCA-PBC Study Group Hepatol (Baltimore, MD MD)"},{"key":"R11-10-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840100102","article-title":"Prognosis in primary biliary cirrhosis: model for decision making.","volume":"10","author":"Dickson","year":"1989","journal-title":"Hepatology (Baltimore, MD)"},{"key":"R12-10-20210226","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1872-034X.2011.00844.x","article-title":"Primary biliary cirrhosisautoimmune hepatitis overlap syndrome: a rationale for corticosteroids use based on a nation-wide retrospective study in Japan.","volume":"41","author":"Tanaka","year":"2011","journal-title":"Hepatol Res"},{"key":"R13-10-20210226","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.hepres.2004.04.001","article-title":"Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis.","volume":"29","author":"Itakura","year":"2004","journal-title":"Hepatol Res"},{"key":"R14-10-20210226","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","article-title":"Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses.","volume":"326","author":"Song","year":"2003","journal-title":"BMJ"},{"key":"R15-10-20210226","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2165\/00019053-200826090-00006","article-title":"Use of indirect and mixed treatment comparisons for technology assessment.","volume":"26","author":"Sutton","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"R16-10-20210226","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"R17-10-20210226","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaborations tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R18-10-20210226","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-2288-11-41","article-title":"Quantifying displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics.","volume":"11","author":"Bowden","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"R19-10-20210226","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis.","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology (Baltimore, MD)"},{"key":"R20-10-20210226","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1097\/MD.0000000000000379","article-title":"Systematic review with network meta-analysis: adjuvant chemotherapy for resected colorectal liver metastases.","volume":"94","author":"Zhu","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R21-10-20210226","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/apt.12900","article-title":"Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer.","volume":"40","author":"Zhu","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R22-10-20210226","first-page":"1158","article-title":"The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study.","volume":"22","author":"Lindor","year":"1995","journal-title":"Hepatology (Baltimore, MD)"},{"key":"R23-10-20210226","first-page":"133","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: results of a controlled study.","volume":"24","author":"Leuschner","year":"1989","journal-title":"Zeitschrift Gastroenterol Verhandlungsband"},{"key":"R24-10-20210226","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/BF02779195","article-title":"A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis.","volume":"25","author":"Oka","year":"1990","journal-title":"Gastroenterol Jpn"},{"key":"R25-10-20210226","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group.","volume":"324","author":"Poupon","year":"1991","journal-title":"N Engl J Med"},{"key":"R26-10-20210226","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0168-8278(05)80214-4","article-title":"Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial Italian Multicenter Group for the Study of UDCA in PBC.","volume":"17","author":"Battezzati","year":"1993","journal-title":"J Hepatol"},{"key":"R27-10-20210226","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1440-1746.1993.tb01189.x","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a short-term, randomized, double-blind controlled, cross-over study with long-term follow up.","volume":"8","author":"Hwang","year":"1993","journal-title":"J Gastroenterol Hepatol"},{"key":"R28-10-20210226","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1440-1746.1994.tb01237.x","article-title":"A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis.","volume":"9","author":"Turner","year":"1994","journal-title":"J Gastroenterol Hepatol"},{"key":"R29-10-20210226","first-page":"759","article-title":"A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis.","volume":"22","author":"Combes","year":"1995","journal-title":"Hepatology (Baltimore, MD)"},{"key":"R30-10-20210226","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/0016-5085(95)90696-7","article-title":"A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid.","volume":"108","author":"Vuoristo","year":"1995","journal-title":"Gastroenterology"},{"key":"R31-10-20210226","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/00365529709000190","article-title":"Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study.","volume":"32","author":"Eriksson","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"R32-10-20210226","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0168-8278(97)80294-2","article-title":"The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone.","volume":"27","author":"Gonzalez-Koch","year":"1997","journal-title":"J Hepatol"},{"key":"R33-10-20210226","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.","volume":"28","author":"Chazouilleres","year":"1998","journal-title":"Hepatology (Baltimore, MD)"},{"key":"R34-10-20210226","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"key":"R35-10-20210226","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1046\/j.1365-2036.2000.00869.x","article-title":"Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis.","volume":"14","author":"Almasio","year":"2000","journal-title":"Aliment Pharmacol Therap"},{"key":"R36-10-20210226","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","article-title":"Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver.","volume":"32","author":"Pares","year":"2000","journal-title":"J Hepatol"},{"key":"R37-10-20210226","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1046\/j.1365-2036.2001.01018.x","article-title":"Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients.","volume":"15","author":"Battezzati","year":"2001","journal-title":"Aliment Pharmacol Therap"},{"key":"R38-10-20210226","first-page":"1195","article-title":"Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.","volume":"49","author":"Gunsar","year":"2002","journal-title":"Hepato-gastroenterology"},{"key":"R39-10-20210226","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1572-0241.2002.05923.x","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial.","volume":"97","author":"Papatheodoridis","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R40-10-20210226","first-page":"573","article-title":"Bezafibrate treatment: a new medical approach for PBC patients J G","volume":"38","author":"Kanda","year":"2003","journal-title":"astroenterol"},{"key":"R41-10-20210226","first-page":"441","article-title":"Therapy response and outcome of overlap syndromes: autoimmune hepatitis and primary biliary cirrhosis compared to autoimmune hepatitis and autoimmune cholangitis.","volume":"57","author":"Ozaslan","year":"2010","journal-title":"Hepato-gastroenterology"},{"key":"R42-10-20210226","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.cgh.2011.05.010","article-title":"Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis.","volume":"9","author":"Leung","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R43-10-20210226","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/hep.20897","article-title":"Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis.","volume":"42","author":"Combes","year":"2005","journal-title":"Hepatology (Baltimore, MD)"},{"key":"R44-10-20210226","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","article-title":"The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study.","volume":"38","author":"Iwasaki","year":"2008","journal-title":"Hepatol Res"},{"key":"R45-10-20210226","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/sim.3594","article-title":"Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation.","volume":"28","author":"Cooper","year":"2009","journal-title":"Stat Med"},{"key":"R46-10-20210226","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.","volume":"330","author":"Poupon","year":"1994","journal-title":"N Engl J Med"},{"key":"R47-10-20210226","doi-asserted-by":"crossref","first-page":"490731","DOI":"10.1155\/2013\/490731","article-title":"Combination therapy of ursodeoxycholic Acid and corticosteroids for primary biliary cirrhosis with features of autoimmune hepatitis: a meta-analysis.","volume":"2013","author":"Zhang","year":"2013","journal-title":"Gastroenterol Res Pract"},{"key":"R48-10-20210226","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jhep.2005.10.017","article-title":"Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.","volume":"44","author":"Chazouilleres","year":"2006","journal-title":"J Hepatol"},{"key":"R49-10-20210226","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0399-8320(07)89323-7","article-title":"Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease.","volume":"31","author":"Heurgue","year":"2007","journal-title":"Gastroenterol Clin Biol"},{"key":"R50-10-20210226","first-page":"CD009145","article-title":"Bezafibrate for primary biliary cirrhosis.","volume":"1","author":"Rudic","year":"2012","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000000609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T02:46:00Z","timestamp":1747795560000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201503030-00010"}},"subtitle":["Efficacy and Safety of UDCA-Based Therapies in Primary Biliary Cirrhosis"],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000000609","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}